2006-2020年美国FDA前列腺癌注册试验的种族报告与多样性
分析2006-2020年FDA前列腺癌药物注册试验的种族多样性与报告合规性,共17项新药注册涉及10种药物、18455名参与者,其中白人占76.3%、黑人仅2.9%;53%的许可发表报告了种族,但仅55%符合FDA建议。非白人参与者显著不足,种族报告不一致,需优先招募黑人和少数族裔。
要点
- 前列腺癌FDA注册试验中黑人仅占2.9%,白人占76.3%,少数族裔显著不足。
- 仅53%的许可发表报告种族,其中仅55%符合FDA建议。
- 种族未报告时,88%的研究在临床试验报告中有补充信息。
核心结论
- FDA前列腺癌药物注册试验中非白人参与者显著不足。
- 许可发表中的种族报告不一致,FDA和ICMJE指南未普遍遵循。
- 应优先招募黑人和其它少数族裔参与者。
研究设计与样本
- 回顾性分析2006-2020年FDA前列腺癌新药注册试验及其许可发表文献。
- 共17项新药注册涉及10种独特药物,18455名参与者。
主要发现
- 参与者种族分布:白人76.3%,亚洲人7.9%,黑人2.9%,美洲印第安人/阿拉斯加原住民0.5%,夏威夷原住民/太平洋岛民0.1%,其他/多种种族1.8%,未知10.5%。
- 53%的试验在许可发表中报告了种族,其中仅55%符合当前FDA建议。
- 种族未报告时,88%的研究在临床研究报告中有进一步信息。
临床怎么用
- 解读前列腺癌药物注册试验结果时需注意少数族裔代表性不足。
- 关注许可发表中种族报告是否符合FDA建议以评估证据外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is significant racial disparity in prostate cancer (PCa) in terms of incidence, treatment, and outcomes. Racial diversity and compliance with FDA race reporting guidelines in PCa drug registration trials are unknown. We analyzed racial diversity and race reporting in drug licensing trials for PCa. METHODS: New drug authorizations for PCa from 2006 to 2020 were identified. The corresponding licensing trial publications were analyzed to check compliance with current FDA recommendations for race reporting. If race was unreported, the clinical trial report was analyzed to determine participant recruitment by race and lead the recruiting country. RESULTS: During the study period, 17 new drug registrations for the management of PCa involving ten unique drugs were identified. In total, 18,455 participants were included in FDA registration trials, of which 76.3% were white or Caucasian, 7.9% Asian, 2.9% Black or African American, 0.5% American Indian or Alaskan Native, 0.1% Native Hawaiian or other Pacific Islander, 1.8% other or multiple races and 10.5% unknown. 53% of trials reported race in the licensing publication, however of this only 55% met current FDA recommendations. When the race was unreported in the licensing publication, 88% of studies had further information in the clinical study report. CONCLUSION: We found a significant under-representation of non-white participants in FDA drug registration trials for PCa. Race reporting in licensing publication is inconsistent and both FDA and International Committee of Medical Journal Editors guidelines are not being universally followed. Given the disproportionality of the disease burden of PCa, recruitment of Black and other minority participants to trials should be a research priority.
引用
- Lythgoe MP, Krell J, Savage P, et al. Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020. Prostate Cancer Prostatic Dis. 2021. PMID: 33859363. doi:10.1038/s41391-021-00361-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。